JAGUAR HEALTH, INC. (JAGX) Spending and interest coverage
- R&D / revenue · 12 months: Value 90.72%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 2.07%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value -25.95×; Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 90.72% | Research and development expense / revenue. Period ending 2026-06-30. $25.23M ÷ $27.82M × 100 ≈ 90.72% |
| Stock-based compensation / revenue · 12 months | 2.07% | Share-based compensation / revenue. Period ending 2026-06-30. $577.00K ÷ $27.82M × 100 ≈ 2.07% |
| Interest coverage · 12 months | -25.95× | Operating income ÷ reported interest expense. $-25.89M ÷ $998.00K ≈ -25.95× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 25.23M USD | Research and Development Expense |
| Revenue | 27.82M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 577.00K USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -25.89M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | 998.00K USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $25.23M | $27.82M | $577.00K | $-25.89M | $998.00K | 90.72% | 2.07% | -25.95× | Reported |
| 2026-03-31 | $25.16M | $29.57M | $685.00K | $-26.30M | $822.00K | 85.10% | 2.32% | -32.00× | Reported |
| 2025-12-31 | $24.97M | $11.51M | $831.00K | $-45.91M | $67.00K | 216.89% | 7.22% | -685.19× | Reported |
| 2025-09-30 | $15.19M | $11.79M | $1.09M | $-32.82M | $-175.00K | 128.87% | 9.22% | (m) | Reported |
| 2025-06-30 | $15.57M | $11.81M | $1.26M | $-32.85M | $-343.00K | 131.85% | 10.64% | (m) | Reported |
| 2025-03-31 | $15.96M | $11.55M | $1.36M | $-32.04M | $-436.00K | 138.16% | 11.78% | (m) | Reported |
| 2024-12-31 | $16.54M | $11.69M | $1.64M | $-30.83M | $231.00K | 141.52% | 14.04% | -133.47× | Reported |
| 2024-09-30 | $15.47M | (m) | $1.85M | $-30.23M | $589.00K | (m) | (m) | -51.33× | Reported |
| 2024-06-30 | $17.51M | (m) | $2.07M | $-31.76M | $1.25M | (m) | (m) | -25.38× | Reported |
| 2024-03-31 | $18.13M | (m) | $2.21M | $-32.66M | $4.81M | (m) | (m) | -6.79× | Reported |
| 2023-12-31 | $18.60M | (m) | $2.11M | $-34.29M | $6.38M | (m) | (m) | -5.37× | Reported |
| 2023-09-30 | $19.44M | (m) | $2.03M | $-33.02M | $8.77M | (m) | (m) | -3.77× | Reported |
| 2023-06-30 | $19.30M | (m) | $2.15M | $-34.13M | $11.00M | (m) | (m) | -3.10× | Reported |
| 2023-03-31 | $17.48M | (m) | $2.73M | $-32.51M | $10.71M | (m) | (m) | -3.04× | Reported |
| 2022-12-31 | $17.65M | $11.96M | $3.32M | $-34.41M | $12.72M | 147.60% | 27.75% | -2.70× | Reported |
| 2022-09-30 | $18.82M | (m) | $3.96M | $-38.95M | $12.52M | (m) | (m) | -3.11× | Reported |
| 2022-06-30 | $16.19M | (m) | $4.39M | $-38.59M | $11.87M | (m) | (m) | -3.25× | Reported |
| 2022-03-31 | $17.61M | (m) | $4.40M | $-43.70M | $10.71M | (m) | (m) | -4.08× | Reported |
| 2021-12-31 | $15.08M | (m) | $3.97M | $-40.71M | $8.42M | (m) | (m) | -4.83× | Reported |
| 2021-09-30 | $11.50M | (m) | $3.47M | $-35.05M | $7.52M | (m) | (m) | -4.66× | Reported |
| 2021-06-30 | $9.71M | (m) | $2.98M | $-30.89M | $6.02M | (m) | (m) | -5.13× | Reported |
| 2021-03-31 | $7.25M | (m) | $2.70M | $-27.76M | $4.49M | (m) | (m) | -6.18× | Reported |
| 2020-12-31 | $6.41M | $9.38M | $2.82M | $-26.65M | $2.79M | 68.33% | 30.09% | -9.54× | Reported |
| 2020-09-30 | $5.90M | $8.32M | $3.19M | $-27.30M | $1.43M | 70.98% | 38.35% | -19.06× | Reported |
| 2020-06-30 | $5.69M | $6.52M | $3.62M | $-28.66M | $2.20M | 87.29% | 55.62% | -13.00× | Reported |
| 2020-03-31 | $5.98M | $5.05M | $3.32M | $-30.83M | $5.38M | 118.33% | 65.72% | -5.73× | Reported |
| 2019-12-31 | $5.82M | $5.78M | $2.99M | $-28.95M | $5.73M | 100.77% | 51.75% | -5.05× | Reported |
| 2019-09-30 | $5.74M | $5.86M | $2.59M | $-35.23M | $6.00M | 97.84% | 44.17% | -5.87× | Reported |
| 2019-06-30 | $5.91M | $6.02M | $2.16M | $-35.01M | $5.52M | 98.13% | 35.86% | -6.34× | Reported |
| 2019-03-31 | $5.82M | $5.20M | $2.18M | $-31.47M | $2.57M | 111.86% | 41.88% | -12.23× | Reported |
| 2018-12-31 | $5.15M | $4.42M | $2.02M | $-30.82M | $2.63M | 116.73% | 45.83% | -11.73× | Reported |
| 2018-09-30 | $5.08M | $4.36M | $1.60M | $-39.39M | $2.59M | 116.44% | 36.69% | -15.18× | Reported |
| 2018-06-30 | $4.45M | $4.33M | $1.11M | $-40.23M | $2.19M | 102.76% | 25.57% | -18.39× | Reported |
| 2018-03-31 | $3.77M | $4.34M | $858.82K | $-35.50M | $1.63M | 86.85% | 19.77% | -21.76× | Reported |
| 2017-12-31 | $4.27M | $4.36M | $814.61K | $-34.25M | $1.21M | 97.90% | 18.68% | -28.31× | Reported |
| 2017-09-30 | $4.57M | $2.85M | $870.41K | $-16.88M | $1.01M | 160.40% | 30.56% | -16.68× | Reported |
| 2017-06-30 | $5.68M | $1.80M | $933.03K | $-12.72M | $782.76K | 316.08% | 51.89% | -16.25× | Reported |
| 2017-03-31 | $6.71M | $925.79K | $842.42K | $-13.78M | $881.38K | 724.85% | 91.00% | -15.63× | Reported |
| 2016-12-31 | $7.21M | $141.52K | $717.93K | $-13.59M | $985.55K | 5092.36% | 507.29% | -13.79× | Reported |
| 2016-09-30 | $7.73M | (m) | $642.56K | $-14.11M | $1.06M | (m) | (m) | -13.34× | Reported |
| 2016-06-30 | $7.01M | $195.14K | $593.38K | $-13.69M | $986.64K | 3590.69% | 304.08% | -13.88× | Reported |
| 2016-03-31 | $6.80M | $234.14K | $1.04M | $-13.45M | $2.67M | 2906.19% | 445.50% | -5.04× | Reported |
| 2015-12-31 | $6.48M | $258.38K | $992.16K | $-12.45M | $3.32M | 2506.32% | 383.99% | -3.75× | Reported |
| 2015-09-30 | $1.17M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $1.05M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $-6.57K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $28.76K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |